REFERENCES

1. Franco N. Animal experiments in biomedical research: a historical perspective. Animals. 2013;3:238-73.

2. Kinter LB, Dehaven R, Johnson DK, Degeorge JJ. A brief history of use of animals in biomedical research and perspective on non-animal alternatives. ILAR J. 2021;62:7-16.

3. European Animal Research Association. Rare diseases - individually rare but collectively common. Available from: https://www.eara.eu/diseases/rare-diseases [Last accessed on 9 Aug 2026].

4. Murillo-Cuesta S, Artuch R, Asensio F, et al. The value of mouse models of rare diseases: a spanish experience. Front Genet. 2020;11:583932.

5. Vallender EJ, Hotchkiss CE, Lewis AD, et al. Nonhuman primate genetic models for the study of rare diseases. Orphanet J Rare Dis. 2023;18:20.

6. Hou N, Du X, Wu S. Advances in pig models of human diseases. Anim Models Exp Med. 2022;5:141-52.

7. Pinnapureddy AR, Stayner C, Mcewan J, Baddeley O, Forman J, Eccles MR. Large animal models of rare genetic disorders: sheep as phenotypically relevant models of human genetic disease. Orphanet J Rare Dis. 2015;10:107.

8. Hytönen MK, Lohi H. Canine models of human rare disorders. Rare Dis. 2016;4:e1241362.

9. Niesman IR. Stress and the domestic cat: have humans accidentally created an animal mimic of neurodegeneration? Front Neurol. 2024;15:1429184.

10. Cannarozzi G, Schneider A, Gonnet G. A phylogenomic study of human, dog, and mouse. PLoS Comput Biol. 2007;3:e2.

11. Lyons LA. Precision medicine in cats—The right biomedical model may not be the mouse! PLoS Genet. 2020;16:e1009177.

12. Jagadesan S, Mondal P, Carlson MA, Guda C. Evaluation of five mammalian models for human disease research using genomic and bioinformatic approaches. Biomedicines. 2023;11:2197.

13. Maynard LH, Humbert O, Peterson CW, Kiem H. Genome editing in large animal models. Mol Ther. 2021;29:3140-52.

14. Partridge T. Myoblast transplantation. Neuromuscul Disord. 2002;12:S3-6.

15. Lelovas PP, Kostomitsopoulos NG, Xanthos TT. A comparative anatomic and physiologic overview of the porcine heart. J Am Assoc Lab Anim Sci. 2014;53:432-8.

16. Ziegler A, Gonzalez L, Blikslager A. Large animal models: the key to translational discovery in digestive disease research. Cell Mol Gastroenterol Hepatol. 2016;2:716-24.

17. Casal M, Haskins M. Large animal models and gene therapy. Eur J Hum Genet. 2005;14:266-72.

18. Halliday JE, Meredith AL, Knobel DL, Shaw DJ, Bronsvoort BMDC, Cleaveland S. A framework for evaluating animals as sentinels for infectious disease surveillance. J Royal Soc Interface. 2007;4:973-84.

19. Partridge B, Rossmeisl JH. Companion animal models of neurological disease. J Neurosci Methods. 2020;331:108484.

20. The role of companion animals as sentinels for predicting environmental exposure effects on aging and cancer susceptibility in humans. Washington DC: National Academies of Sciences, Engineering, and Medicine, 2021. Available from: https://nap.nationalacademies.org/resource/26547/HLs_Companion_Animals.pdf [Last accessed on 9 Aug 2026].

21. Sanvictores T, Mahabadi N, Rehman CI. Classical conditioning (archived). Treasure Island (FL): StatPearls Publishing, 2024.

22. Creed RS, Denny-Brown D, Eccles JC, Liddell EGT, Sherrington CS. Reflex activity of the spinal cord. Oxford: The Clarendon Press, 1932. Available from: https://archive.org/details/reflexactivityof0000rscr_s0e5 [Last accessed on 9 Aug 2026].

23. Sherrington CS. Observations on the scratch reflex in the spinal dog. J Physiol. 1906;34:1-50.

24. Parrey MUR. From cats to the cortex: unravelling the hierarchical processing system of vision and brain plasticity. Cureus. 2024;16:e68424.

25. Klumpers F, Morgan B, Terburg D, Stein DJ, Van Honk J. Impaired acquisition of classically conditioned fear-potentiated startle reflexes in humans with focal bilateral basolateral amygdala damage. Soc Cogn Affect Neurosci. 2015;10:1161-8.

26. Matesanz S, Mcguire JL, Hopkins S. Acute flaccid myelitis: characteristics and outcomes of 2014 and 2016 cases at a single center. J Pediatr. 2019;215:272-276.e1.

27. Hailaiti A, Yu X, Yao K, Shentu X. Postoperative amblyopia in children with congenital cataracts: a systematic review and meta-analysis. Ital J Pediatr. 2025;51:141.

28. Heinonen T, Flegel T, Müller H, et al. A loss-of-function variant in canine GLRA1 associates with a neurological disorder resembling human hyperekplexia. Hum Genet. 2023;142:1221-30.

29. Shelton GD, Engvall E. Canine and feline models of human inherited muscle diseases. Neuromuscul Disord. 2005;15:127-38.

30. Gurda BL, Bradbury AM, Vite CH. Canine and feline models of human genetic diseases and their contributions to advancing clinical therapies. Yale J Biol Med. 2017;90:417-31.

31. King TA. The one medicine concept: its emergence from history as a systematic approach to re-integrate human and veterinary medicine. Emerg Top Life Sci. 2021;5:643-54.

32. Jacobs AC, Hatfield KP. History of chronic toxicity and animal carcinogenicity studies for pharmaceuticals. Vet Pathol. 2012;50:324-33.

33. Lehman AJ, Patterson WI, Davidow B, et al. Procedures for the appraisal of the toxicity of chemicals in foods, drugs and cosmetics. Food Drug Cosmet Law J. 1955;10:679-748.

34. Bower N, Achanzar WE, Boulifard V, Brinck PR, Kittel B, Vahle JL. The dog as a second species for toxicology testing provides value to drug development. Int J Toxicol. 2022;41:431-41.

35. Monticello TM, Jones TW, Dambach DM, et al. Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: the IQ consortium nonclinical to clinical translational database. Toxicol Appl Pharmacol. 2017;334:100-9.

36. Leenaars CHC, Kouwenaar C, Stafleu FR, et al. Animal to human translation: a systematic scoping review of reported concordance rates. J Transl Med. 2019;17:223.

37. Ferreira GS, Veening-Griffioen DH, Boon WPC, Moors EHM, Van Meer PJK. Levelling the translational gap for animal to human efficacy data. Animals. 2020;10:1199.

38. Ineichen BV, Furrer E, Grüninger SL, Zürrer WE, Macleod MR. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications. PLoS Biol. 2024;22:e3002667.

39. Kiani AK, Pheby D, Henehan G, et al. Ethical considerations regarding animal experimentation. J Prev Med Hyg. 2022;63:E255-66.

40. Congress.Gov. S.5002 - FDA modernization act 2.0. Available from: https://www.congress.gov/bill/117th-congress/senate-bill/5002 [Last accessed on 24 Aug 2026].

41. Han JJ. FDA modernization act 2.0 allows for alternatives to animal testing. Artif Organs. 2023;47:449-50.

42. Wadman M. FDA no longer has to require animal testing for new drugs. Science. 2023;379:127-8.

43. Congress.Gov. S.355. FDA modernization act 3.0. Available from: https://www.congress.gov/bill/119th-congress/senate-bill/355 [Last accessed on 14 Aug 2026].

44. Imberechts D, Ny A, Copmans D. Established and emerging new approach methodologies in neuroscience. Front Neurosci. 2025;19:1696937.

45. Mirlohi MS, Yousefi T, Aref AR, Seyfoori A. Integrating new approach methodologies (NAMs) into preclinical regulatory evaluation of oncology drugs. Biomimetics. 2025;10:796.

46. Michaeli DT, Michaeli T, Albers S, Boch T, Michaeli JC. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur J Health Econ. 2023;25:979-97.

47. Saltonstall P, Ross H, Kim PT. The Orphan Drug Act at 40: legislative triumph and the challenges of success. Milbank Q. 2023;102:83-96.

48. Mao X, Alexander GC, Li G. Accelerated approvals: early-phase success or premature authorization? Cancer Cell. 2024;42:1799-802.

49. Soave OA. Animal experimentation leading to better care of laboratory and pet animals. Am J Public Health Nations Health. 1967;57:1621-6.

50. Ewald BH, Gregg DA. Animal research for animals. Ann N Y Acad Sci. 2006;406:48-58.

51. Loew FM. Animals as beneficiaries of biomedical research originally intended for humans. ILAR J. 2021;62:367-8.

52. Dickinson PJ, Bannasch M, Thomasy SM, et al. Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis. J Vet Intern Med. 2020;34:1587-93.

53. Meij BP, Van Stee LL. Transsphenoidal surgery for pituitary tumors. Vet Clin North Am Small Anim Pract. 2025;55:95-118.

54. Rusbridge C. Chiari-like malformation with syringomyelia in the cavalier king charles spaniel: long-term outcome after surgical management. Vet Surg. 2007;36:396-405.

55. Graves SS, Storb R. Evolution of haematopoietic cell transplantation for canine blood disorders and a platform for solid organ transplantation. Vet Med Sci. 2021;7:2156-71.

56. Windsor RC, Stewart S, Cassano JM, et al. Intravenous allogeneic mesenchymal stromal cell therapy in 13 Pugs with presumptive early necrotizing meningoencephalitis. J Am Vet Med Assoc. 2025;263:1-10.

57. Doshi BS, Samelson-Jones BJ, Nichols TC, et al. AAV gene therapy in companion dogs with severe hemophilia: real-world long-term data on immunogenicity, efficacy, and quality of life. Mol Ther Methods Clin Dev. 2024;32:101205.

58. Gürkan H, Satkın NB. The importance of genetic diagnosis in rare diseases. Balkan Med J. 2025;42:92-3.

59. National Organization for Rare Disorders (NORD). Available from: https://rarediseases.org/ [Last accessed on 16 Aug 2026].

60. European accessibility act vs. Americans with disabilities act (ADA): key differences. Available from: https://usattorneys.com/european-accessibility-act-vs-americans-with-disabilities-act-ada-key-differences/ [Last accessed on 16 Aug 2026].

61. Auvin S, Irwin J, Abi-Aad P, Battersby A. The problem of rarity: estimation of prevalence in rare disease. Value Health. 2018;21:501-7.

62. H.R.5238 - Orphan Drug Act. Available from: https://www.congress.gov/bill/97th-congress/house-bill/5238 [Last accessed on 16 Aug 2026].

63. Act on Medical Care for Patients with Intractable Diseases (Act No. 50 of 2014). Available from: https://www.japaneselawtranslation.go.jp/en/laws/view/3363/en [Last accessed on 16 Aug 2026].

64. Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products. Available from: https://eur-lex.europa.eu/eli/reg/2000/141/oj/eng [Last accessed on 16 Aug 2026].

65. Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs, and their regulation in Asia: current status and future perspectives. Intractable Rare Dis Res. 2012;1:3-9.

66. Rosenberg N, Van Den Berg S, Stolwijk NN, et al. Access to medicines for rare diseases: a European regulatory roadmap for academia. Front Pharmacol. 2023;14:1142351.

67. Federal Registry. Defining small number of animals for minor use determination; Periodic reassessment. Available from: https://www.federalregister.gov/documents/2022/09/15/2022-19954/defining-small-number-of-animals-for-minor-use-determination-periodic-reassessment [Last accessed on 16 Aug 2026].

68. FDA provides for more treatments for dogs and cats to qualify for minor use status. Available from: https://www.fda.gov/animal-veterinary/cvm-updates/fda-provides-more-treatments-dogs-and-cats-qualify-minor-use-status#:~:text=The%20FDA%20has%20increased%20the%20threshold%20of,Conditional%20Approval%20*%20Waivers%20from%20user%20fees [Last accessed on 16 Aug 2026].

69. US pet ownership statistics. Available from: https://www.avma.org/resources-tools/reports-statistics/us-pet-ownership-statistics [Last accessed on 16 Aug 2026].

70. Karyopharm announces: FDA considers the effectiveness and safety technical sections complete to support conditional approval for the new animal drug application for verdinexor (KPT-335) to treat lymphoma in client owned dogs. Available from: https://investors.karyopharm.com/2014-05-16-Karyopharm-Announces-FDA-Considers-the-Effectiveness-and-Safety-Technical-Sections-Complete-to-Support-Conditional-Approval-for-the-New-Animal-Drug-Application-for-Verdinexor-KPT-335-to-Treat-Lymphoma-in-Client-Owned-Dogs [Last accessed on 16 Aug 2026].

71. Loss CM. Veterinarians should understand what it means to use conditionally approved drugs, with a focus on conditional approval of companion animal oncology drugs. J Am Vet Med Assoc. 2022;260:1562-5.

72. CVM GFI #261 - Eligibility criteria for expanded conditional approval of new animal drugs. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-261-eligibility-criteria-expanded-conditional-approval-new-animal-drugs [Last accessed on 18 Aug 2026].

73. FDA conditionally approves drug for management of ventricular hypertrophy in cats. Available from: https://www.fda.gov/animal-veterinary/cvm-updates/fda-conditionally-approves-drug-management-ventricular-hypertrophy-cats [Last accessed on 16 Aug 2026].

74. FDA completes safety for gallant’s first ready-to-use stem cell therapy for refractory FCGS. Available from: https://www.gallant.com/news/fda-completes-safety-for-gallants-first-ready-to-use-stem-cell-therapy-for-refractory-fcgs/ [Last accessed on 16 Aug 2026].

75. Soltero-Rivera M, Hart S, Blandino A, Vapniarsky N, Arzi B. Mesenchymal stromal cell therapy for feline chronic gingivostomatitis: Long term experience. Front Vet Sci. 2023;10:1171922.

76. Veterinary limited markets. Available from: https://www.ema.europa.eu/en/veterinary-regulatory-overview/research-development-veterinary-medicines/veterinary-limited-markets#:~:text=The%20Regulation%20aims%20to%20further,requirements%20and%20enhanced%20regulatory%20assistance [Last accessed on 16 Aug 2026].

77. Weiss MG, Agashe M, Gupte MD. The concept of one health: cultural context, background & prospects in India. Indian J Med Res. 2021;153:333-7.

78. One Health History. In one health, centers for disease control. Available from: https://www.cdc.gov/one-health/about/one-health-history.html [Last accessed on 14 Aug 2026].

79. Cardiff RD, Ward JM, Barthold SW. ‘One medicine—one pathology': are veterinary and human pathology prepared? Lab Investig. 2008;88:18-26.

80. Pettan-Brewer C, Penn G, Biondo AW, Jaenisch T, Grützmacher K, Kahn LH. Who coined the term “One Health”? Cooperation amid the siloization. One Health. 2024;18:100678.

81. Stroud C, Dmitriev I, Kashentseva E, et al. A one health overview, facilitating advances in comparative medicine and translational research. Clin Transl Med. 2016;5:e26.

82. Rath A, Salamon V, Peixoto S, et al. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome? Trials. 2017;18:556.

83. Macy J, Horvath TL. Comparative medicine: an inclusive crossover discipline. Yale J Biol Med. 2017;90:493-8.

84. Mcentire KD, Gage M, Gawne R, et al. Understanding drivers of variation and predicting variability across levels of biological organization. Integr Comp Biol. 2021;61:2119-31.

85. Frey HH, Löscher W. Clinical pharmacokinetics of phenytoin in the dog: a reevaluation. Am J Vet Res. 1980;41:1635-8.

86. Chow L, Wheat W, Ramirez D, Impastato R, Dow S. Direct comparison of canine and human immune responses using transcriptomic and functional analyses. Sci Rep. 2024;14:2207.

87. Reinholdt L, Chesler E, Pera M, Rosenthal N. The rare-to-common disease journey: a winding road to new therapies. Trends Genet. 2025;41:762-73.

88. Davidson BA, Hassan S, Garcia EJ, Tayebi N, Sidransky E. Exploring genetic modifiers of Gaucher disease: the next horizon. Hum Mutat. 2018;39:1739-51.

89. Crisp MJ, Beckett J, Coates JR, Miller TM. Canine degenerative myelopathy: biochemical characterization of superoxide dismutase 1 in the first naturally occurring non-human amyotrophic lateral sclerosis model. Exp Neurol. 2013;248:1-9.

90. Kingdom R, Wright CF. Incomplete penetrance and variable expressivity: from clinical studies to population cohorts. Front Genet. 2022;13:920390.

91. Rahit KMTH, Tarailo-Graovac M. Genetic modifiers and rare mendelian disease. Genes. 2020;11:239.

92. Fehr A, Prütz F. Rare diseases: a challenge for medicine and public health. J Health Monit. 2023;8:3-6.

93. Dhengale M, Bathe H, Hage P, Challenges and innovations in conducting clinical trials in rare and orphan diseases, et al. Int J Sci Res Technol 2025;2:427-41.

94. Vavassori S, Russell S, Scotti C, Benvenuti S. Unlocking the full potential of rare disease drug development: exploring the not-for-profit sector’s contributions to drug development and access. Front Pharmacol. 2024;15:1441807.

95. Sutherland S. Why are there so few drugs approved specifically for veterinary use. Available from: https://www.anivive.com/learn/article/why-are-there-so-few-drug-approved-specifically-for-veterinary-use [Last accessed on 15 Aug 2026].

96. Vashi N, Justice MJ. Treating rett syndrome: from mouse models to human therapies. Mamm Genome. 2019;30:90-110.

97. Gunes D, Karaca M, Durmus A, et al. Challenges in the clinical management of rare diseases and center-based multidisciplinary approach to creating solutions. Eur J Pediatr. 2025;184:281.

98. Yokoshiki S, Arato T. Implementation status of pharmacological studies in the development of orphan drugs. Orphanet J Rare Dis. 2024;19:5.

99. Yates N, Hinkel J. The economics of moonshots: value in rare disease drug development. Clin Transl Sci. 2022;15:809-12.

100. Phares S, Trusheim M, Emond SK, Pearson SD. Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States. J Comp Eff Res. 2024;13:e240118.

101. Patterson AM, O’boyle M, Vannoy GE, Dies KA. Emerging roles and opportunities for rare disease patient advocacy groups. Ther Adv Rare Dis. 2023;4:26330040231164425.

102. Chehade M, Meyers S, Mccright-Gill T, et al. Collaboration as a catalyst for advancing rare disease research: the experience of the rare diseases clinical research network. Clin Transl Sci. 2026;19:e70585.

103. The Comparative Oncology Trials Consortium. Available from: https://ccr.cancer.gov/comparative-oncology-program/trials-consortium [Last accessed on 15 Aug 2026].

104. Lenz JA, Atherton MJ. Maximizing the dual benefit of pet dogs in cancer trials. Nat Rev Cancer. 2025;25:147-8.

105. Moore SA, O’kell A, Borghese H, et al. A CTSA one health alliance guidance on institutional review of veterinary clinical studies. BMC Vet Res. 2021;17:83.

106. Tan MH, Thomas M, Maceachern MP. Using registries to recruit subjects for clinical trials. Contemp Clin Trials. 2015;41:31-8.

107. Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013;28:1142-50.

108. American Kennel Club Canine Health Foundation. Participate in research. Available from: https://www.akcchf.org/research/participate-in-research/ [Last accessed on 15 Aug 2026].

109. Quigley M, Mckenna C, Webb TL. Best practices for recruitment in veterinary clinical trials. Front Vet Sci. 2024;11:1418747.

110. AKC Canine Health Foundation awards first research grant through the comparative brain tumor consort. Available from: https://www.akc.org/expert-advice/news/chf-awards-first-research-grant/ [Last accessed on 15 Aug 2026].

111. Zhu Q, Nguyễn Ð, Sheils T, et al. Scientific evidence based rare disease research discovery with research funding data in knowledge graph. Orphanet J Rare Dis. 2021;16:483.

112. NIH under fire for funding dog tests despite vow to cut animal research. The Guardian. Available from: https://www.theguardian.com/us-news/2025/jul/16/nih-animal-testing-dogs-cats [Last accessed on 15 Aug 2026].

113. The NHGRI Dog Genome Project. Available from: https://research.nhgri.nih.gov/dog_genome/ [Last accessed on 15 Aug 2026].

114. Acland GM, Ray K, Mellersh CS, et al. A novel retinal degeneration locus identified by linkage and comparative mapping of canine early retinal degeneration. Genomics. 1999;59:134-42.

115. Karyadi DM, Karlins E, Decker B, et al. A copy number variant at the KITLG locus likely confers risk for canine squamous cell carcinoma of the digit. PLoS Genet. 2013;9:e1003409.

116. NIH to prioritize human-based research technologies. Available from: https://www.nih.gov/news-events/news-releases/nih-prioritize-human-based-research-technologies [Last accessed on 15 Aug 2026].

117. Rare disease advocacy organizations. Available from: https://www.gaucherdisease.org/about-gaucher-disease/resources/rare-disease-advocacy-organizations/ [Last accessed on 15 Aug 2026].

118. National organization for rare disorders (NORD) announces annual seed grant RFPs totaling $245,000 to accelerate research for five rare diseases. Available from: https://rarediseases.org/national-organization-for-rare-disorders-nord-announces-annual-seed-grant-rfps-totaling-245000-to-accelerate-research-for-five-rare-diseases/ [Last accessed on 15Aug 2026].

119. American Kennel Club Canine Health Foundation. Advancing scientific discovery in canine health. Available from: https://www.akcchf.org/ [Last accessed on 15 Aug 2026].

120. Every Cat Health Foundation. Funding groundbreaking research to advance feline medicine. Available from: https://everycat.org/the-latest/grants/ [Last accessed on 15 Aug 2026].

121. Yahoo!finance. AKC Canine Health Foundation earns top ratings from two leading independent charity evaluations. Available from: https://finance.yahoo.com/healthcare/articles/akc-canine-health-foundation-earns-150000801.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAAmc-M3N8IOKCeyeysj6U0QFG0rXPsBIrsD6iW7yNk2ieSCPHaezm1G08R-Npk44lZikn_VTKr90AntltwNG-vues6b1n-7GP1TUMpuS1jppKczf_aVSyRxWATeXtluoeJQC3RzVLyi8gHpwt3fgfFKD4Gq79iJnB1Tc3ThgzG-6 [Last accessed on 15 Aug 2026].

122. AKC Canine Health Foundation. 01185-A: Hemophilia A in golden retriever search for the causative mutation. Available from: https://www.akcchf.org/grant-directory/01185-a/ [Last accessed on 15 Aug 2026].

123. AKC Canine Health Foundation. AKC Canine Health Foundation-fund the cutting edge: canine osteosarcoma hope in viral therapy treatment. Available from: https://www.akcchf.org/press-release/osteosarcoma-canine-health/ [Last accessed on 15 Aug 2026].

124. CABI Digital Library. Stem cell study to aid dogs suffering from degenerative myelopathy. Available from: https://www.cabidigitallibrary.org/do/10.5555/collection-news-17015/full/ [Last accessed on 15 Aug 2026].

125. Glikin GC, Finocchiaro LME. Clinical trials of cancer immunogene therapies in companion animals: an update (2017-2024). Vet Sci. 2025;12:329.

126. Petersen-Jones SM, Beckwith-Cohen B. Gene therapy advances using canine and feline animal models of inherited retinal degeneration. Eye. 2025;39:2143-50.

127. Rasmussen HB, Thomsen R, Hansen PR. Nucleoside analog GS-441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid-19. Pharmacol Res Perspec. 2022;10:e00945.

128. Skipper AM, Packer RMA, O’neill DG. Researcher, research thyself? Mapping the landscape of canine health and welfare research funding provided by UK not-for-profit organisations from 2012-2022. PLoS ONE. 2024;19:e0303498.

129. Doshi BS, Crudele JM, Callan MB. Adeno-associated viral vector gene therapy for canine hemophilia. Rare Dis Orphan Drugs J. 2026;5:7.

130. Ceva Sante Animalé acquires Scout Bio, paving the way for groundbreaking innovations in pet therapeutics. Available from: https://www.ceva.com/press-release/ceva-sante-animale-acquires-scout-bio-paving-the-way-for-groundbreaking-innovations-in-pet-therapeutics/ [Last accessed on 15 Aug 2026].

131. Rejuvenate Bio. A gene therapy approach to treating chronic, age-related disease. Available from: https://rejuvenatebio.com/ [Last accessed on 15 Aug 2026].

132. Landfeldt E. Gene therapy for neuromuscular diseases: health economic challenges and future perspectives. J Neuromuscul Dis. 2022;9:675-88.

133. Williams C. At-cost AAV: from production cost to patient dose. 2024. Available from: https://desciappliedresearch.com/2024/01/at-cost-aav/ [Last accessed on 15 Aug 2026].

134. Windsor R. Stem cell therapy for rare neurological diseases: translational research opportunities. Rare Dis Orphan Drugs J. 2026;5:11.

135. Edmunds GL, Mason NJ. Immunotherapeutic advances for the treatment of osteosarcoma, driven by studies in pet dogs with spontaneous disease. Rare Dis Orphan Drugs J. 2026:5.

136. Ng QX, Ong C, Chan KE, et al. Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review. Health Econ Rev. 2024;14:42.

137. Metz J. Pet insurance statistics. 2025. Available from: https://www.forbes.com/advisor/pet-insurance/pet-insurance-statistics/#sources_section [Last accessed on 15 Aug 2026].

138. Pet insurance penetration rates by country: where are the biggest MGA opportunities? 2026. Available from: https://insurnest.com/blog/pet-insurance-mga-penetration-rates-by-country/ [Last accessed on 15 Aug 2026].

139. Pet Benefit Solutions. Pet insurance versus human health insurance: what’s the difference? Available from: https://www.petbenefits.com/blog/pet-insurance-versus-human-health-insurance-whats-the-difference/ [Last accessed on 15 Aug 2026].

140. Steere K. Pet insurance vs. human health insurance: key differences to know. Available from: https://www.pawlicy.com/blog/pet-insurance-vs-human-health-insurance/ [Last accessed on 15 Aug 2026].

141. Debes C, Wowra J, Manzoor S, Ruple A. Predicting health outcomes in dogs using insurance claims data. Sci Rep. 2023;13:9122.

142. Williams A, Williams B, Hansen CR, Coble KH. The impact of pet health insurance on dog owners’ spending for veterinary services. Animals. 2020;10:1162.

143. Applied Market Research. Pet insurance market (2023-2033). Available from: https://www.alliedmarketresearch.com/pet-insurance-market [Last accessed on 15 Aug 2026].

144. Stephens JL. How angel’s story could save your dog’s life. Pets Best, 2011. Available from: https://www.petsbest.com/blog/how-angels-story-could-save-dog [Last accessed on 15 Aug 2026].

145. Veterinary Practice News. Trupanion adds rare procedures to standard pet insurance policy. 2014. Available from: https://www.veterinarypracticenews.com/trupanion-adds-rare-procedures-to-standard-pet-insurance-policy/ [Last accessed on 15 Aug 2026].

146. CNBC Select. Best pet insurance for pre-existing conditions. 2026. Available from: https://www.cnbc.com/select/best-pet-insurance-pre-existing-conditions/ [Last accessed on 15 Aug 2026].

147. Braga LH, Farrokhyar F, Dönmez Mİ, et al. Randomized controlled trials - the what, when, how and why. J Pediatr Urol. 2025;21:397-404.

148. Cyske Z, Radzanowska-Alenowicz E, Rintz E, Gaffke L, Pierzynowska K. The rare disease burden: a multidimensional challenge. Acta Biochim Pol. 2025;72:14777.

149. Megalizzi D, Trastulli G, Colantoni L, et al. Deciphering the complexity of FSHD: a multimodal approach as a model for rare disorders. Int J Mol Sci. 2024;25:10949.

150. Adams LS, Miller JL, Grady PA. The spectrum of caregiving in palliative care for serious, advanced, rare diseases: key issues and research directions. J Palliat Med. 2016;19:698-705.

151. Verhalen B, Arnold S, Minassian B. Lafora disease: a review of molecular mechanisms and pathology. Neuropediatrics. 2018;49:357-62.

152. Hajek I, Kettner F, Simerdova V, et al. NHLRC1 repeat expansion in two beagles with Lafora disease. J Small Anim Pract. 2016;57:650-2.

153. Swain L, Key G, Tauro A, et al. Lafora disease in miniature Wirehaired Dachshunds. PLoS ONE. 2017;12:e0182024.

154. von Klopmann T, Ahonen S, Espadas-Santiuste I, et al. Canine lafora disease: an unstable repeat expansion disorder. Life. 2021;11:689.

155. Flegel T, Dirauf C, Kehl A, et al. Clinical signs in 166 beagles with different genotypes of lafora. Genes. 2024;15:122.

156. ZAFRA-Puerta L, Iglesias-Cabeza N, Burgos DF, et al. Gene therapy for Lafora disease in the Epm2a mouse model. Mol Ther. 2024;32:2130-49.

157. Charalambous M, Fischer A, Potschka H, et al. Translational veterinary epilepsy: a win-win situation for human and veterinary neurology. Vet J. 2023;293:105956.

158. Donohue KJ, Fitzsimmons B, Bruntz RC, et al. Gys1 antisense therapy prevents disease-driving aggregates and epileptiform discharges in a lafora disease mouse model. Neurotherapeutics. 2023;20:1808-19.

159. Williams MI, Donohue KJ, Sanz P, et al. The 9th annual Lafora science symposium: a rare epilepsy community makes progress towards clinical readiness. Epilepsy Behav. 2025;171:110654.

160. Jonker AH, O’connor D, Cavaller-Bellaubi M, et al. Drug repurposing for rare: progress and opportunities for the rare disease community. Front Med. 2024;11:1352803.

161. Jourdan J, Bureau R, Rochais C, Dallemagne P. Drug repositioning: a brief overview. J Pharm Pharmacol. 2020;72:1145-51.

162. Southall NT, Natarajan M, Lau LPL, et al. The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force. Orphanet J Rare Dis. 2019;14:225.

163. Yoo H. Development of orphan drugs for rare diseases. Clin Exp Pediatr. 2024;67:315-27.

164. Mag P, Nemes-Terényi M, Jerzsele Á, Mátyus P. Some aspects and convergence of human and veterinary drug repositioning. Molecules. 2024;29:4475.

165. Gokalsing E, Ferrolho J, Gibson MS, Vilhena H, Anastácio S. Efficacy of GS-441524 for feline infectious peritonitis: a systematic review (2018-2024). Pathogens. 2025;14:717.

166. Cerna P, Coggins S, Blyth M, Reagan KL. From ebola to feline infectious peritonitis: the cross-species journey of GS-441524 and the future of antiviral translation. Rare Dis Orphan Drugs J. 2026;5:20.

167. Spatola GJ, Ostrander EA, Mousseau TA. The effects of ionizing radiation on domestic dogs: a review of the atomic bomb testing era. Biol Rev. 2021;96:1799-815.

168. Fiorentino A, Gregucci F, Desideri I, et al. Radiation treatment for adult rare cancers: oldest and newest indication. Crit Rev Oncol Hematol. 2021;159:103228.

169. Vanhaezebrouck IF, Scarpelli ML. Companion animals as a key to success for translating radiation therapy research into the clinic. Cancers. 2023;15:3377.

170. Heidner GL, Kornegay JN, Page RL, Dodge RK, Thrall DE. Analysis of survival in a retrospective study of 86 dogs with brain tumors. J Vet Intern Med. 1991;5:219-26.

171. MagalhÃes TR, BenoÎt J, NÉČovÁ S, North S, Queiroga FL. Outcome after radiation therapy in canine intracranial meningiomas or gliomas. In Vivo. 2021;35:1117-23.

172. Kundapur V, Mayer M, Auer RN, et al. Is mini beam ready for human trials? Results of randomized study of treating de-novo brain tumors in canines using linear accelerator generated mini beams. Radiat Res. 2022;198:162-71.

173. Gieger TL. Radiation therapy for brain tumors in dogs and cats. Vet Clin North Am Small Anim Pract. 2025;55:67-80.

174. Comparative Brain Tumor Consortium. Available from: https://ccr.cancer.gov/comparative-oncology-program/comparative-brain-tumor-consortium [Last accessed on 16 Aug 2026].

175. Beck JA, Mazcko C, Belluco S, et al. Comparative pathology boards facilitate the translation of knowledge between canine and human cancer patients. Brain Pathol. 2025;35:e70013.

176. Leblanc AK, Mazcko C, Brown DE, et al. Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients. Neuro Oncol. 2016;18:1209-18.

177. Thrall DE, Larue SM, Po BE. Use of whole body hyperthermia as a method to heat inaccessible tumours uniformly: a phase III trial in canine brain masses. Int J Hyperthermia. 2009;15:383-98.

178. Schuh EM, Portela R, Gardner HL, Schoen C, London CA. Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. BMC Vet Res. 2017;13:294.

179. Wylleman B, Brancato L, Gorbaslieva I, et al. Tolerability of long-term temperature controlled whole-body thermal treatment in advanced cancer-bearing dogs. Int J Hyperthermia. 2021;39:48-56.

180. Obrador E, Moreno-Murciano P, Oriol-Caballo M, et al. Glioblastoma therapy: past, present and future. Int J Mol Sci. 2024;25:2529.

181. Zhang S, Wang X, Gao X, et al. Radiopharmaceuticals and their applications in medicine. Sig Transduct Target Ther. 2025;10:1.

182. Khan MK, Nasti TH, Buchwald ZS, Weichselbaum RR, Kron SJ. Repurposing drugs for cancer radiotherapy: early successes and emerging opportunities. Cancer J. 2019;25:106-15.

183. Salgueiro MJ, Zubillaga M. Strategic objectives of nanotechnology-driven repurposing in radiopharmacy—implications for radiopharmaceutical repurposing (beyond oncology). Pharmaceutics. 2025;17:1159.

184. Designating an orphan product: drugs and biological products. Available from: https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products [Last accessed on 16 Aug 2026].

185. Swanson DP. Radiopharmaceuticals as orphan drugs. Semin Nucl Med. 1996;26:91-5.

186. Maitz CA, Bryan JN. The role of companion animal models in radiopharmaceutical development and translation. Vet Comp Oncol. 2024;22:165-73.

187. Dare AJ, Anderson BO, Sullivan R, et al. Surgical services for cancer care. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Disease control priorities, third edition; 2015. pp. 223-38.

188. Van Stee L, Van Der Steen F, Galac S, Kooistra H, Meij B. Rare pituitary diseases in dogs and cats and their human companions. Rare Dis Orphan Drugs J. 2026;5:19.

189. Ricca RL, Penn E. Surgical support of the developmentally delayed or neurologically impaired child. Surg Clin North Am. 2022;102:847-60.

190. Ghasemi Shayan R, Fatollahzadeh Dizaji M, Sajjadian F. Surgical and postoperative management of congenital heart disease: a systematic review of observational studies. Langenbeck's Arch Surg. 2025;410:113.

191. Jones R, Rusbridge C, Cirovic S. Computational modelling of cerebrospinal fluid flow in a translational canine model. Rare Dis Orphan Drugs J. 2026;5:24.

192. Cucu AI, Costea CF, Perciaccante A, Donell ST, Bianucci R. The evolution of pituitary gland surgery from the ancients to the millennials. World Neurosurg. 2023;180:52-65.

193. Van Stee LL, Van Rijn SJ, Galac S, Meij BP. Challenges of transsphenoidal pituitary surgery in severe brachycephalic dogs. Front Vet Sci. 2023;10:1154617.

194. Lindholm J. Cushing's syndrome: historical aspects. Pituitary. 2000;3:97-104.

195. Massardi E, Gaudenzi G, Carra S, et al. Cushing’s disease in the animal Kingdom: translational insights for human medicine. Int J Mol Sci. 2025;26:8626.

196. Polledo L, Grinwis GCM, Graham P, Dunning M, Baiker K. Pathological findings in the pituitary glands of dogs and cats. Vet Pathol. 2018;55:880-8.

197. Sanders K, Galac S, Meij B. Pituitary tumour types in dogs and cats. Vet J. 2021;270:105623.

198. Castellanos LE, Gutierrez C, Smith T, Laws ER, Iorgulescu JB. Epidemiology of common and uncommon adult pituitary tumors in the U.S. according to the 2017 World Health Organization classification. Pituitary. 2021;25:201-9.

199. Mukherjee P, Roy S, Ghosh D, Nandi SK. Role of animal models in biomedical research: a review. Lab Anim Res. 2022;38:18.

200. Kwananocha I, Magré J, Verseijden F, et al. Pilot study on the use of an off-the-shelf 3D-printed titanium acetabular rim extension implant for treating canine hip dysplasia. Res Vet Sci. 2025;191:105668.

201. Woody LR, Guiot LP, Garcia TC, Hudson CC, Sadowitz M, Marcellin-Little DJ. A lateral approach allows accurate and stable total elbow replacement in dogs. Am J Vet Res. 2024;85:ajvr.24.04.0100.

202. Ferguson RJ, Palmer AJ, Taylor A, Porter ML, Malchau H, Glyn-Jones S. Hip replacement. Lancet. 2018;392:1662-71.

203. Willemsen K, Möring MM, Harlianto NI, et al. Comparing hip dysplasia in dogs and humans: a review. Front Vet Sci. 2021;8:791434.

204. Tong Y, Ihejirika-Lomedico R, Rathod P, Deshmukh A. Approaching total hip arthroplasty after Legg-Calvé-Perthes disease: a case series and literature review. J Clin Orthop Trauma. 2024;53:102478.

205. Roh Y, Heo S, Yoon J, Park J, Jeong S, Lee H. Micro total hip replacement in two dogs with Legg-Calvé-Perthes disease. J Vet Clin. 2017;34:454-8.

206. Matsuura K, Yoshida T, Yamada S, et al. The outcome of surgical mitral valve repair with loop-in-loop technique in dogs with different stage myxomatous mitral valve disease. J Vet Cardiol. 2022;42:74-82.

207. Brockman DJ, Holt DE, Gaynor JW, Theman TE. Long-term palliation of tetralogy of Fallot in dogs by use of a modified Blalock-Taussig shunt. J Am Vet Med Assoc. 2007;231:721-6.

208. Bradshaw A, Bradshaw JC, Quinn R, Briscoe JB, Lawton JS. 80 years after the first blalock-thomas-taussig shunt: cardiac research in canines that saved lives. J Surg Res. 2025;312:252-62.

209. Elverum K, Whitman M. Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicine. Gene Ther. 2019;27:537-44.

210. Baek HJ, Nam Y, Rim YA, Ju JH. Advances in cell and gene therapy for rare disease treatment. Int J Stem Cells. 2025;18:324-37.

211. Locquet P, Reckelbus M, Van Steijvoort E, et al. Public perception and willingness to accept somatic gene therapy: a Belgian survey study. Open Res Eur. 2026;5:319.

212. Switonski M. Impact of gene therapy for canine monogenic diseases on the progress of preclinical studies. J Appl Genet. 2020;61:179-86.

213. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet. 2001;28:92-5.

214. Segelken HR. Gene therapy restores vision to dogs blinded by inherited disease, bringing new hope to childhood sufferers of similar condition. Cornell Chronicle, 2001. Available from: https://news.cornell.edu/stories/2001/04/gene-therapy-restores-vision-dogs-blinded-inherited-disease-bringing-new-hope [Last accessed on 16 Aug 2026].

215. Gilger BC. How study of naturally occurring ocular disease in animals improves ocular health globally. J Am Vet Med Assoc. 2022;260:1887-93.

216. Bradbury AM, Gurda BL, Casal ML, Ponder KP, Vite CH, Haskins ME. A review of gene therapy in canine and feline models of lysosomal storage disorders. Hum Gene Ther Clin Dev. 2015;26:27-37.

217. Nichols T, Hough C, Agersø H, Ezban M, Lillicrap D. Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies. J Thromb Haemost. 2016;14:894-905.

218. Soufizadeh P, Mansouri V, Ahmadbeigi N. A review of animal models utilized in preclinical studies of approved gene therapy products: trends and insights. Lab Anim Res. 2024;40:17.

219. Birch SM, Lawlor MW, Conlon TJ, et al. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Sci Transl Med. 2023;15:eabo1815.

220. Teixeira J, Burke MJ, Herzog RW, Duan D. Canine model of duchenne muscular dystrophy. In: Flanigan K, Nicolau S, editors. Duchenne muscular dystrophy. New York, NY: Springer; 2025. pp. 203-38.

221. Vite CH, Gurda BL, Porter FD, Casal ML. Diagnosis and therapy of niemann-pick disease type C1- what have we learned that can help veterinary patients? Rare Dis Orphan Drugs J. 2026;5:23.

222. Thomas ED. Bone marrow transplantation - past, present, and future, 1990. Available from: www.nobelprize.org/prizes/medicine/1990/thomas/lecture/ [Last accessed on 16 Aug 2026].

223. Bair SM, Brandstadter JD, Ayers EC, Stadtmauer EA. Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. Cancer. 2020;126:1837-55.

224. Cortez AJP, Dulley FL, Saboya R, et al. Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma. Rev Bras Hematol Hemoter. 2010;33:10-4.

225. Dell'agnola C, Wang Z, Storb R, et al. Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs. Blood. 2004;104:4311-8.

226. Kornegay JN, Bogan JR, Bogan DJ, et al. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome. 2012;23:85-108.

227. Tominari T, Sathyaprakash C, Aoki Y. Stem/progenitor cell-based therapy for Duchenne muscular dystrophy. Front Cell Dev Biol. 2025;13:1640275.

228. Newman R, Yoo D, Leroux M, Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets. 2009;8:110-23. 2009;8:110.

229. Han X, Liao R, Li X, et al. Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies. Sig Transduct Target Ther. 2025;10:262.

230. Guest DJ, Dudhia J, Smith RKW, et al. Position statement: minimal criteria for reporting veterinary and animal medicine research for mesenchymal stromal/stem cells in orthopedic applications. Front Vet Sci. 2022;9:817041.

231. Kim H, Shin T. Canine and feline mesenchymal stem cells: an integrative review of direct comparative studies by species and tissue source. J Vet Sci. 2025;26:e78.

232. Yin Y, Boesteanu AC, Binder ZA, et al. Checkpoint blockade reverses anergy in IL-13Rα2 humanized scFv-based CAR T cells to treat murine and canine gliomas. Mol Ther Oncolytics. 2018;11:20-38.

233. Olin MR, Ampudia-Mesias E, Pennell CA, et al. Treatment combining CD200 immune checkpoint inhibitor and tumor-lysate vaccination after surgery for pet dogs with high-grade glioma. Cancers. 2019;11:137.

234. Panek WK, Toedebusch RG, Mclaughlin BE, et al. The CCL2-CCR4 axis promotes regulatory T cell trafficking to canine glioma tissues. J Neurooncol. 2024;169:647-58.

235. Ammons DT, Guth A, Rozental AJ, et al. Reprogramming the canine glioma microenvironment with tumor vaccination plus oral losartan and propranolol induces objective responses. Cancer Res Commun. 2022;2:1657-67.

236. Jackson M, Marks L, May GH, Wilson JB. The genetic basis of disease. Essays Biochem. 2018;62:643-723.

237. Caterina Anton S, Lazan A, Grigore M, et al. Current trends in breast cancer genetics, risk factors, and screening strategies. J Biol Methods. 2025;12:e99010054.

238. Pasaol JC, Śmieszek A, Pawlak A. Exploring the therapeutic potential of BRCA1 and BRCA2 as targets in canine oncology: a comprehensive review of their role in cancer development and treatment. Int J Mol Sci. 2025;26:1768.

239. Ouellette J, Lacoste B. From neurodevelopmental to neurodegenerative disorders: the vascular continuum. Front Aging Neurosci. 2021;13:749026.

240. Shabani K, Hassan BA. The brain on time: links between development and neurodegeneration. Development. 2023;150:dev200397.

241. Lloyd-Evans E, Haslett LJ. The lysosomal storage disease continuum with ageing-related neurodegenerative disease. Ageing Res Rev. 2016;32:104-21.

242. Onyenwoke RU, Brenman JE. Lysosomal storage diseases-regulating neurodegeneration. J Exp Neurosci. 2016;9s2:JEN.S25475.

243. Lindblad-Toh K, Wade CM, Mikkelsen TS, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature. 2005;438:803-19.

244. Pontius JU, Mullikin JC, Smith DR, et al. Initial sequence and comparative analysis of the cat genome. Genome Res. 2007;17:1675-89.

245. Li RHL, Ontiveros E, Nguyen N, et al. Precision medicine identifies a pathogenic variant of the ITGA2B gene responsible for Glanzmann's thrombasthenia in a cat. J Vet Intern Med. 2020;34:2438-46.

246. Woerde DJ, Palm CA, Cosaro EC, et al. A novel missense variant in the calcium-sensing receptor gene in a dog with hypercalcemia. J Vet Intern Med. 2026;40:aalaf046.

247. Wenger DA. Globoid cell leukodystrophy in Cairn and West Highland white terriers. J Hered. 1999;90:138-42.

248. Bellumori TP, Famula TR, Bannasch DL, Belanger JM, Oberbauer AM. Prevalence of inherited disorders among mixed-breed and purebred dogs: 27,254 cases (1995-2010). J Am Vet Med Assoc. 2013;242:1549-55.

249. Donner J, Anderson H, Davison S, et al. Frequency and distribution of 152 genetic disease variants in over 100,000 mixed breed and purebred dogs. PLoS Genet. 2018;14:e1007361.

250. Hadar BN, Bonnett BN, Poljak Z, Bernardo TM. Morbidity of insured Swedish cats between 2011 and 2016: comparing disease risk in domestic crosses and purebreds. Vet Rec. 2023;192:e2778.

251. Kier AB, Bresnahan JF, White FJ, Wagner JE. The inheritance pattern of factor XII (Hageman) deficiency in domestic cats. Can J Comp Med. 1980;44:309-14.

252. Walvoort HC. Glycogen storage disease type II in the Lapland dog. Vet Q. 1985;7:187-90.

253. Crawford KC, Dreger DL, Shelton GD, Ekenstedt KJ, Lewis MJ. Juvenile-onset motor polyneuropathy in Siberian cats. J Vet Intern Med. 2020;34:2595-604.

254. Melniczek JR, Dambach D, Prociuk U, et al. Sry-negative XX sex reversal in a family of norwegian elkhounds. J Vet Intern Med. 1999;13:564.

255. Oh JH, Cho J. Comparative oncology: overcoming human cancer through companion animal studies. Exp Mol Med. 2023;55:725-34.

256. Giuliano A. Companion animal model in translational oncology; feline oral squamous cell carcinoma and canine oral melanoma. Biology. 2021;11:54.

257. Stull JW, Anderson ME, Weese JS. The dynamic nature of canine and feline infectious disease risks in the twenty-first century. Vet Clin North Am Small Anim Pract. 2019;49:587-98.

258. Kilham L, Margolis G, Colby ED. Congenital infections of cats and ferrets by feline panleukopenia virus manifested by cerebellar hypoplasia. Lab Invest. 1967;17:465-80.

259. Crumlish PT, Sweeney T, Jones B, Angles JM. Hypertrophic osteodystrophy in the Weimaraner dog: lack of association between DQA1 alleles of the canine MHC and hypertrophic osteodystrophy. Vet J. 2006;171:308-13.

260. Coates JR, Wininger FA. Canine degenerative myelopathy. Vet Clin North Am Small Anim Pract. 2010;40:929-50.

261. Georgy SR. Lysosomal storage diseases. J Vet Anim Sci. 2021;52:1-6.

262. Comparative Oncology Program. Available from: https://ccr.cancer.gov/comparative-oncology-program [Last accessed on 17 Aug 2026].

263. Leblanc AK, Breen M, Choyke P, et al. Perspectives from man’s best friend: national academy of medicine’s workshop on comparative oncology. Sci Transl Med. 2016;8:324ps5.

264. Compton ZT, Mellon W, Harris VK, et al. Cancer prevalence across vertebrates. Cancer Discov. 2025;15:227-44.

265. Vincze O, Colchero F, Lemaître J, et al. Cancer risk across mammals. Nature. 2021;601:263-7.

266. Nunney L, Maley CC, Breen M, Hochberg ME, Schiffman JD. Peto's paradox and the promise of comparative oncology. Phil Trans R Soc B. 2015;370:20140177.

267. Makielski KM, Mills LJ, Sarver AL, et al. Risk factors for development of canine and human osteosarcoma: a comparative review. Vet Sci. 2019;6:48.

268. Dolnicka A, Fosse V, Raciborska A, Śmieszek A. Building a therapeutic bridge between dogs and humans: a review of potential cross-species osteosarcoma biomarkers. Int J Mol Sci. 2025;26:5152.

269. Simpson S, Dunning MD, De Brot S, Grau-Roma L, Mongan NP, Rutland CS. Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics. Acta Vet Scand. 2017;59:71.

270. Dobson JM. Breed-predispositions to cancer in pedigree dogs. ISRN Vet Sci. 2013;2013:1-23.

271. Borges RSDM, Da Silva PHS, Pimentel PAB, et al. Surgical approaches to canine appendicular osteosarcoma part 2 - limb-sparing techniques. Front Vet Sci. 2025;12:1655874.

272. Chow L, Ammons D, Dow SW. Role of companion dogs in cancer immunotherapy development. J Immunol. 2025;214:2515-22.

273. NIH-funded canine immunotherapy data center charts a path toward transformative therapies. Available from: https://penntoday.upenn.edu/news/nih-funded-canine-immunotherapy-data-center-charts-path-toward-transformative-therapies [Last accessed on 17 Aug 2026].

274. Berndt SI, Cavalli F, Smedby KE. Non-hodgkin lymphoma: complex etiology, including the role of immune function. In: Wild CP, Weiderpass E, Stewart BW, editors. World Cancer report: cancer research for cancer prevention. Lyon (FR): International Agency for Research on Cancer, 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK606529/ [Last accessed on 17 Aug 2026].

275. Ito D, Frantz AM, Modiano JF. Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. Vet Immunol Immunopathol. 2014;159:192-201.

276. Economu L, Stell A, O'neill DG, Schofield I, Stevens K, Brodbelt D. Incidence and risk factors for feline lymphoma in UK primary‐care practice. J Small Anim Pract. 2020;62:97-106.

277. Seelig D, Avery A, Ehrhart E, Linden M. The comparative diagnostic features of canine and human lymphoma. Vet Sci. 2016;3:11.

278. Ghimire P. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17:697.

279. Paulin MV, Couronné L, Beguin J, et al. Feline low-grade alimentary lymphoma: an emerging entity and a potential animal model for human disease. BMC Vet Res. 2018;14:306.

280. Parisi F, Fonti N, Millanta F, Freer G, Pistello M, Poli A. Exploring the link between viruses and cancer in companion animals: a comprehensive and comparative analysis. Infect Agent Cancer. 2023;18:40.

281. Hartmann K. Clinical aspects of feline retroviruses: a review. Viruses. 2012;4:2684-710.

282. Schneider R. Comparison of age- and sex-specific incidence rate patterns of the leukemia complex in the cat and the dog. J Natl Cancer Inst. 1983;70:971-7.

283. Louwerens M, London CA, Pedersen NC, Lyons LA. Feline lymphoma in the post-feline leukemia virus era. J Vet Intern Med. 2005;19:329-35. [PMID:15954547 DOI:10.1892/0891.

284. Pimentel PAB, Giuliano A, Da Costa FVA, et al. Feline lymphoma associated with feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) infections in Brazil- Systematic review. Vet Anim Sci. 2025;30:100514.

285. Zhang Y, Guo W, Zhan Z, Bai O. Carcinogenic mechanisms of virus-associated lymphoma. Front Immunol. 2024;15:1361009.

286. Prevedel NE, Mee MW, Wood GA, Coomber BL. Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro. Vet Comp Oncol. 2024;22:96-105.

287. Pui Yung Anna L, Horta R, Sze CN, Giuliano A. Use of cyclophosphamide, vincristine, prednisolone and vinblastine for the treatment of large cell lymphoma in cats. J Vet Intern Med. 2025;39:jvim70066.

288. Wheeler A, Dansby D, Hawkins H, Payne H, Weikel J. A toxicologic and hematologic evaluation of cyclophosphamide (Cytoxan®) in experimental animals. Toxicol Appl Pharmacol. 1962;4:324-43.

289. Harrison SD. An investigation of the mouse as a model for vincristine toxicity. Cancer Chemother Pharmacol. 1983;11:62-5.

290. Ogilvie GK, Richardson RC, Curtis CR, et al. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc. 1989;195:1584-7.

291. Siewert JM, Gustafson DL, Weishaar KM, Galloway AM, Thamm DH. Individualized chemotherapy drug dose escalation in dogs with multicentric lymphoma. J Vet Intern Med. 2023;37:2402-9.

292. Hartmann K, Wooding A, Bergmann M. Efficacy of antiviral drugs against feline immunodeficiency virus. Vet Sci. 2015;2:456-76.

293. Policicchio BB, Pandrea I, Apetrei C. Animal models for HIV cure research. Front Immunol. 2016;7:12.

294. Westman M, Hall E, Norris J, Meili T, Hofmann‐Lehmann R, Malik R. Antiviral therapy in cats progressively infected with feline leukaemia virus: lessons from a series of 18 consecutive cases from Australia. Aust Vet J. 2024;102:453-65.

295. Akhtar N, Mishra R, Tripathi S, et al. Feline immunodeficiency virus: current insights into pathogenesis, clinical impact, and advances in treatment and vaccine development. Front Vet Sci. 2025;12:1665999.

296. Le Poder S. Feline and canine coronaviruses: common genetic and pathobiological features. Adv Virol. 2011;2011:1-11.

297. Paltrinieri S, Giordano A, Stranieri A, Lauzi S. Feline infectious peritonitis (FIP) and coronavirus disease 19 (COVID-19): are they similar? Transbound Emerg Dis. 2020;68:1786-99.

298. Attipa C, Warr AS, Epaminondas D, et al. Feline infectious peritonitis epizootic caused by a recombinant coronavirus. Nature. 2025;645:228-34.

299. Sykes JE. Feline coronavirus infection. Canine and feline infectious diseases. Elsevier; 2014. pp. 195-208.

300. Cook SE, Vogel H, Castillo D, Olsen M, Pedersen N, Murphy BG. Investigation of monotherapy and combined anticoronaviral therapies against feline coronavirus serotype II in vitro. J Feline Med Surg. 2021;24:943-53.

301. Gilead Sciences. Available from: https://www.gilead.com/ [Last accessed on 17 Aug 2026].

302. Zuzzi-Krebitz A, Buchta K, Bergmann M, et al. Short treatment of 42 days with oral GS-441524 results in equal efficacy as the recommended 84-day treatment in cats suffering from feline infectious peritonitis with effusion—a prospective randomized controlled study. Viruses. 2024;16:1144.

303. Accessing antiviral treatment for FIP. Available from: https://www.fipvetguide.com/access-to-treatment#:~:text=Compounded%20GS%2D441524%20is%20available,preparation%20from%20specials%20compounder%20BOVA [Last accessed on 17 Aug 2026].

304. Taylor SS, Coggins S, Barker EN, et al. Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020-2022). J Feline Med Surg. 2023;25:1098612X231194460.

305. FDA announces position on use of compounded GS-441524 to treat FIP. Available from: https://www.fda.gov/animal-veterinary/cvm-updates/fda-announces-position-use-compounded-gs-441524-treat-fip#:~:text=Because%20no%20FDA%20approved%20drug,a%20nomination%20for%20GS%2D441524 [Last accessed on 17 Aug 2026].

306. Dowdy SM. Feline Infectious peritonitis: from fatal to treatable. DVM360. 2020. Available from: https://www.dvm360.com/view/feline-infectious-peritonitis-fatal-treatable [Last accessed on 19 Aug 2026].

307. Kornegay JN. Feline infectious peritonitis: the central nervous system form. J Am Anim Hosp Assoc. 1978;14:580-4. Available from: https://www.researchgate.net/publication/279597488_Feline_infectious_peritonitis_The_central_nervous_system_form [Last accessed on 19 Aug 2026].

308. Oliver-Guimera A, Murphy BG, Keel MK. The nucleoside analog GS-441524 effectively attenuates the in vitro replication of multiple lineages of circulating canine distemper viruses isolated from wild North American carnivores. Viruses. 2025;17:150.

309. Krakowka S, Mccullough B, Koestner A, Olsen R. Myelin-specific autoantibodies associated with central nervous system demyelination in canine distemper virus infection. Infect Immun. 1973;8:819-27.

310. Achar A, Myers R, Ghosh C. Drug delivery challenges in brain disorders across the blood-brain barrier: novel methods and future considerations for improved therapy. Biomedicines. 2021;9:1834.

311. Kadamus C, Sibi S, Bharadwaj R, Subramony JA. A multimodal perspective to overcome translational barriers in cerebrospinal drug delivery. Expert Opin Drug Deliv. 2025;23:209-20.

312. Gurda BL, De Guilhem De Lataillade A, Bell P, et al. Evaluation of AAV-mediated gene therapy for central nervous system disease in canine mucopolysaccharidosis VII. Mol Ther. 2016;24:206-16.

313. Nichol AA. Emerging infectious diseases at the intersections of human, animal, and environmental health. AMA J Ethics. 2024;26:E99-102.

314. Chomel B. Emerging and re-emerging zoonoses of dogs and cats. Animals. 2014;4:434-45.

315. Wells HL, Bonavita CM, Navarrete-Macias I, Vilchez B, Rasmussen AL, Anthony SJ. The coronavirus recombination pathway. Cell Host Microbe. 2023;31:874-89.

316. Junges L, Galvis D, Winsor A, et al. The impact of paediatric epilepsy and co-occurring neurodevelopmental disorders on functional brain networks in wake and sleep. PLoS ONE. 2024;19:e0309243.

317. Olusanya BO, Gladstone M, Wright SM, et al. Cerebral palsy and developmental intellectual disability in children younger than 5 years: findings from the GBD-WHO rehabilitation database 2019. Front Public Health. 2022;10:894546.

318. Presson AP, Partyka G, Jensen KM, et al. Current estimate of down syndrome population prevalence in the United States. J Pediatr. 2013;163:1163-8.

319. Scandurra V, Emberti Gialloreti L, Barbanera F, Scordo MR, Pierini A, Canitano R. Neurodevelopmental disorders and adaptive functions: a study of children with autism spectrum disorders (ASD) and/or attention deficit and hyperactivity disorder (ADHD). Front Psychiatry. 2019;10:673.

320. Résibois A, Coppens A, Poncelet L. Naturally occurring parvovirus-associated feline hypogranular cerebellar hypoplasia—a comparison to experimentally-induced lesions using immunohistology. Vet Pathol. 2007;44:831-41.

321. Johnson RH, Margolis G, Kilham L. Identity of feline ataxia virus with feline panleucopenia virus. Nature. 1967;214:175-7.

322. Csiza CK, De Lahunta A, Scott FW, Gillespie JH. Pathogenesis of feline panleukopenia virus in susceptible newborn kittens II. Pathology and immunofluorescence. Infect Immun. 1971;3:838-46.

323. Howley MM, Keppler-Noreuil KM, Cunniff CM, Browne ML; for the National Birth Defects Prevention Study. Descriptive epidemiology of cerebellar hypoplasia in the national Birth defects prevention study. Birth Defects Res. 2018;110:1419-32.

324. Patel S, Barkovich AJ. Analysis and classification of cerebellar malformations. AJNR Am J Neuroradiol. 2002;23:1074-87.

325. Jash S, Sharma S. Pathogenic infections during pregnancy and the consequences for fetal brain development. Pathogens. 2022;11:193.

326. Haldipur P, Millen KJ. What cerebellar malformations tell us about cerebellar development. Neurosci Lett. 2019;688:14-25.

327. Kornegay JN. Cerebellar vermian hypoplasia in dogs. Vet Pathol. 1986;23:374-9.

328. Bernardino F, Rentmeister K, Schmidt MJ, et al. Inferior cerebellar hypoplasia resembling a dandy-walker-like malformation in purebred eurasier dogs with familial non-progressive ataxia: a retrospective and prospective clinical cohort study. PLoS ONE. 2015;10:e0117670.

329. Ten Donkelaar HJ, Lammens M, Wesseling P, Thijssen HO, Renier WO. Development and developmental disorders of the human cerebellum. J Neurol. 2003;250:1025-36.

330. Grinberg I, Northrup H, Ardinger H, Prasad C, Dobyns WB, Millen KJ. Heterozygous deletion of the linked genes ZIC1 and ZIC4 is involved in Dandy-Walker malformation. Nat Genet. 2004;36:1053-5.

331. Gerber M, Fischer A, Jagannathan V, et al. A deletion in the VLDLR gene in eurasier dogs with cerebellar hypoplasia resembling a dandy-walker-like malformation (DWLM). PLoS ONE. 2015;10:e0108917.

332. Cotes C, Bonfante E, Lazor J, et al. Congenital basis of posterior fossa anomalies. Neuroradiol J. 2015;28:238-53.

333. Schatzberg SJ, Haley NJ, Barr SC, et al. Polymerase chain reaction (PCR) amplification of parvoviral DNA from the brains of dogs and cats with cerebellar hypoplasia. J Vet Intern Med. 2003;17:538-44.

334. Jones R, Cirovic S, Rusbridge C. A review of cerebrospinal fluid circulation with respect to Chiari-like malformation and syringomyelia in brachycephalic dogs. Fluids Barriers CNS. 2025;22:25.

335. Ocampo-Navia MI, Perez-Mendez W, Rodriguez-Alvarez MP, Chadid-Contreras J, Vergara MF. Dandy-Walker syndrome: an updated literature review. Child's Nerv Syst. 2025;41:194.

336. Sharp N, Davis B, Guy J, Cullen J, Steingold S, Kornegay J. Hydranencephaly and cerebellar hypoplasia in two kittens attributed to intrauterine parvovirus infection. J Comp Pathol. 1999;121:39-53.

337. Schmidt MJ, Farke D. Surgical management of primary and idiopathic internal hydrocephalus in dogs and cats. Front Vet Sci. 2024;11:1435982.

338. Knowler SP, Mcfadyen AK, Freeman C, et al. Quantitative analysis of chiari-like malformation and syringomyelia in the griffon bruxellois dog. PLoS ONE. 2014;9:e88120.

339. Taylor DG, Mastorakos P, Jane JA, Oldfield EH. Two distinct populations of Chiari I malformation based on presence or absence of posterior fossa crowdedness on magnetic resonance imaging. J Neurosurg. 2016;126:1934-40.

340. Tellegen AR, Dessing AJ, Houben K, et al. Dog as a Model for osteoarthritis: the FGF4 retrogene insertion may matter. J Orthop Res. 2019;37:2550-60.

341. Lefort-Holguin M, Delsart A, Frézier M, et al. Osteoarthritis in cats: what we know, and mostly, what we don’t know. . . yet. J Feline Med Surg. 2025;27:1098612X251347999.

342. Bergknut N, Rutges JP, Kranenburg HJ, et al. The dog as an animal model for intervertebral disc degeneration? Spine. 2012;37:351-8.

343. Ebeling R, Lorenz N, Zablotski Y, Meyer-Lindenberg A, Kornmayer M. Feline intervertebral disc disease: a systematic review and meta-analysis. J Feline Med Surg. 2025;27:1098612X251385878.

344. van der Weiden GS, Meij BP, van de Belt A, et al. The modified canine groove model of osteoarthritis. Biomedicines. 2025;13:913.

345. Hong JY, Kim H, Jeon W, et al. Animal models of intervertebral disc diseases: advantages, limitations, and future directions. Neurol Int. 2024;16:1788-818.

346. Morawska-Kozłowska M, Pitas M, Zhalniarovich Y. Mesenchymal stem cells in veterinary medicine-still untapped potential. Animals. 2025;15:1175.

347. Seo M, Park S, Han S, et al. Long-term treatment of allogeneic adipose-derived stem cells in a dog with rheumatoid arthritis. J Vet Sci. 2022;23:e61.

348. Pedersen NC. A review of immunologic diseases of the dog. Vet Immunol Immunopathol. 1999;69:251-342.

349. Aprígio RM, Caramanti RL, Santos FOR, et al. Intradural disc herniation at the L1-L2 level: a case report and literature review. Surg Neurol Int. 2019;10:196.

350. Cooper L, Kent M. Lumbosacral intradural-extramedullary intervertebral disc extrusion in a cat. JFMS Open Rep. 2025;11:20551169251352386.

351. Kim J, Kim H, Hwang J, Eom K. Preliminary study of presumptive intradural-intramedullary intervertebral disc extrusion in 20 dogs. J Vet Sci. 2020;21:e52.

352. Cauzinille L, Kornegay JN. Fibrocartilaginous embolism of the spinal cord in dogs: review of 36 histologically confirmed cases and retrospective study of 26 suspected cases. J Vet Intern Med. 1996;10:241-5.

353. Bartholomew KA, Stover KE, Olby NJ, Moore SA. Clinical characteristics of canine fibrocartilaginous embolic myelopathy (FCE): a systematic review of 393 cases (1973-2013). Vet Rec. 2016;179:650-650.

354. Okada K, Kagawa Y. Fibrocartilaginous embolism of the cervical spinal cord and cerebellum in a cat. J Vet Med Sci. 2019;81:747-9.

355. Abdelrazek MA, Mowla A, Farooq S, Silvestri N, Sawyer R, Wolfe G. Fibrocartilaginous embolism: a comprehensive review of an under-studied cause of spinal cord infarction and proposed diagnostic criteria. J Spinal Cord Med. 2015;39:146-54.

356. De Risio L. A review of fibrocartilaginous embolic myelopathy and different types of peracute non-compressive intervertebral disk extrusions in dogs and cats. Front Vet Sci. 2015;2:24.

357. Katz ML, Rustad E, Robinson GO, et al. Canine neuronal ceroid lipofuscinoses: promising models for preclinical testing of therapeutic interventions. Neurobiol Dis. 2017;108:277-87.

358. Story BD, Miller ME, Bradbury AM, et al. Canine models of inherited musculoskeletal and neurodegenerative diseases. Front Vet Sci. 2020;7:80.

359. Bonifacino T, Zerbo RA, Balbi M, et al. Nearly 30 years of animal models to study amyotrophic lateral sclerosis: a historical overview and future perspectives. Int J Mol Sci. 2021;22:12236.

360. Mcgeachan RI, Ewbank L, Watt M, et al. Amyloid-beta pathology increases synaptic engulfment by glia in feline cognitive dysfunction syndrome: a naturally occurring model of Alzheimer's disease. Eur J Neurosci. 2025;62:e70180.

361. Morgan BR, Coates JR, Johnson GC, Shelton GD, Katz ML. Characterization of thoracic motor and sensory neurons and spinal nerve roots in canine degenerative myelopathy, a potential disease model of amyotrophic lateral sclerosis. J Neurosci Res. 2013;92:531-41.

362. Awano T, Johnson GS, Wade CM, et al. Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2009;106:2794-9.

363. Kaur SJ, Mckeown SR, Rashid S. Mutant SOD1 mediated pathogenesis of amyotrophic lateral sclerosis. Gene. 2016;577:109-18.

364. Kathmann I, Cizinauskas S, Doherr MG, Steffen F, Jaggy A. Daily controlled physiotherapy increases survival time in dogs with suspected degenerative myelopathy. J Vet Intern Med. 2006;20:927-32. [PMID:16955818 DOI:10.1892/0891.

365. Bouché TV, Coates JR, Moore SA, Faissler D, Rishniw M, Olby NJ. Diagnosis and management of dogs with degenerative myelopathy: a survey of neurologists and rehabilitation professionals. J Vet Intern Med. 2023;37:1815-20.

366. Gouveia D, Correia J, Cardoso A, et al. Intensive neurorehabilitation and allogeneic stem cells transplantation in canine degenerative myelopathy. Front Vet Sci. 2023;10:1192744.

367. Van Daele SH, Masrori P, Van Damme P, Van Den Bosch L. The sense of antisense therapies in ALS. Trends Mol Med. 2024;30:252-62.

368. Olby NJ, Panek W, Galifi C, et al. Development and pilot testing of U1 adaptor therapy targeting SOD1 expression for dogs with degenerative myelopathy. J Vet Intern Med. 2026:aalaf072.

369. Platt FM, Boland B, van der Spoel AC. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol. 2012;199:723-34.

370. Jolly RD, Walkley SU. Lysosomal storage diseases of animals: an essay in comparative pathology. Vet Pathol. 1997;34:527-48.

371. Skelly BJ, Franklin RJ. Recognition and diagnosis of lysosomal storage diseases in the cat and dog. J Vet Intern Med. 2002;16:133.

372. Ellinwood NM, Colle M, Weil MA, et al. Bone marrow transplantation for feline mucopolysaccharidosis I. Mol Genet Metab. 2007;91:239-50.

373. Haskins ME. Animal models for mucopolysaccharidosis disorders and their clinical relevance. Acta Paediatr. 2007;96:56-62.

374. Hordeaux J, Jeffrey BA, Jian J, et al. Efficacy and safety of a krabbe disease gene therapy. Hum Gene Ther. 2022;33:499-517.

375. Chung CCY, Chu ATW, Chung BHY; Hong Kong Genome Project. Rare disease emerging as a global public health priority. Front Public Health. 2022;10:1028545.

376. Center for Drug Evaluation and Research (CDER). Available from: https://www.fda.gov/about-fda/fda-organization/center-drug-evaluation-and-research-cder [Last accessed on 18 Aug 2026].

377. Center for Veterinary Medicine. Available from: https://www.fda.gov/about-fda/fda-organization/center-veterinary-medicine [Last accessed on 18 Aug 2026].

378. European Medicines Agency. Available from: https://www.ema.europa.eu/en/homepage [Last accessed on 18 Aug 2026].

379. Pharmaceuticals and Medical Devices Agency (PMDA). Available from: https://www.pmda.go.jp/english/ [Last accessed on 18 Aug 2026].

380. International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). Available from: https://www.ich.org/ [Last accessed on 18 Aug 2026].

381. Committee for Veterinary Medical Products (CVMP). Available from: https://www.ema.europa.eu/en/committees/committee-veterinary-medicinal-products-cvmp [Last accessed on 18 Aug 2026].

382. Outline of Regulation System of Veterinary Medicinal Products (VMPs) in Japan. Available from: https://www.maff.go.jp/nval/english/pdf/outline130325.pdf [Last accessed on 18 Aug 2026].

383. The Drug Development Process. Available from: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process [Last accessed on 18 Aug 2026].

384. ALS Therapy Development Institute. The clinical trials process|The four phases explained. Available from: https://www.als.net/news/the-clinical-trial-process-the-four-phases-explained/ [Last accessed on 18 Aug 2026].

385. Clinical Development Success Rates. Available from: https://ptacts.uspto.gov/ptacts/public-informations/petitions/1498535/download-documents?artifactId=5v_9LXjCDowMBkWYk_yPRH4PU_rjV20njZu2PAaXZXkFMuAjrDmidjg [Last accessed on 21 Aug 2026].

386. Figure 1 food and drug administrations’ (FDA) typical drug development and approval process (35856478702).jpg. Available from: https://commons.wikimedia.org/wiki/File:Figure_1_Food_and_Drug_Administration%E2%80%99s_(FDA)_Typical_Drug_Development_and_Approval_Process_(35856478702).jpg [Last accessed on 21 Aug 2026].

387. Cellular & Gene Therapy Products. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products [Last accessed on 18 Aug 2026].

388. FDA increases flexibility on requirements for cell and gene therapies to advance innovation. Available from: https://www.fda.gov/news-events/press-announcements/fda-increases-flexibility-requirements-cell-and-gene-therapies-advance-innovation [Last accessed on 18 Aug 2026].

389. Considerations for the use of the plausible mechanism framework to develop individualized therapies that target specific genetic conditions with known biological cause. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-plausible-mechanism-framework-develop-individualized-therapies-target-specific [Last accessed on 18 Aug 2026].

390. When a Product Becomes a 351 Biologic. Available from: https://www.novavitalabs.com/post/what-is-a-361-vs-351-product-understanding-fda-regulation-of-human-cells-and-tissues#:~:text=Culture%20expansion%20is%20the%20most,BLA%20before%20marketing%20the%20product [Last accessed on 18 Aug 2026].

391. Knoepfler PS. From bench to FDA to bedside: US regulatory trends for new stem cell therapies. Adv Drug Delivery Rev. 2015;82-3:192-6.

392. Preclinical Studies in Drug Development. Available from: https://www.ppd.com/what-is-a-cro/preclinical-studies-in-drug-development/ [Last accessed on 18 Aug 2026].

393. Ekwall B. Screening of toxic compounds in mammalian cell cultures. Ann N Y Acad Sci. 1983;407:64-77.

394. Goh JY, Weaver RJ, Dixon L, Platt NJ, Roberts RA. Development and use of in vitro alternatives to animal testing by the pharmaceutical industry 1980-2013. Toxicol Res. 2015;4:1297-307.

395. Clinical Research. Step 3. Available from: https://www.fda.gov/patients/drug-development-process/step-3-clinical-research [Last accessed on 18 Aug 2026].

396. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40-51.

397. Mullard A. 2025’s FDA approvals by regulatory designations. Nat Rev Drug Discov. 2026;25:163-163.

398. New Drug Therapy Approvals 2024. Available from: https://www.fda.gov/files/drugs/published/new-drug-therapy-2025-annual-report.pdf#:~:text=Drugs%20for%20Rare%20Diseases.%20In%202024%2C%2026,no%20drugs%20available%20to%20treat%20their%20conditions [Last accessed on 18 Aug 2026].

399. FDA CDER releases 15th annual new drug therapy approvals report for 2025. Available from: https://oncodaily.com/public-health/fda-15#:~:text=Overview%20of%202025%20Drug%20Approvals,diverse%20and%20evolving%20development%20pipeline [Last accessed on 18 Aug 2026].

400. Yamaguchi S, Kaneko M, Narukawa M. Approval success rates of drug candidates based on target, action, modality, application, and their combinations. Clin Transl Sci. 2021;14:1113-22.

401. Harrison RK. Phase II and phase III failures: 2013-2015. Nat Rev Drug Discov. 2016;15:817-8.

402. Bowling H, Cocucci A, Koo DCE, Harrison RK. Analysis of phase II and phase III clinical trial terminations from 2013 to 2023. Nat Rev Drug Discov. 2025;25:345-6.

403. Michaeli T, Jürges H, Michaeli DT. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis. BMJ. 2023;381:e073242.

404. Miller KL, Fermaglich LJ, Maynard J. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet J Rare Dis. 2021;16:265.

405. Koong AJ, Irvin VL, Narayan A, Song S, Kaplan RM. Evidence available and used by the Food and Drug Administration for the approval of orphan and nonorphan drugs. Health Aff Sch. 2025;3:qxaf057.

406. Daniel MG, Pawlik TM, Fader AN, Esnaola NF, Makary MA. The Orphan Drug Act: restoring the mission to rare diseases. Am J Clin Oncol. 2016;39:210-3.

407. Fan M, Chan AYL, Yan VKC, et al. Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018. Orphanet J Rare Dis. 2022;17:3.

408. Fast track, breakthrough therapy, accelerated approval, priority review. Available from: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review [Last accessed on 18 Aug 2026].

409. Darrow JJ, Avorn J, Kesselheim AS. New FDA Breakthrough-drug category—implications for patients. N Engl J Med. 2014;370:1252-8.

410. Bhavsar K, Collins G. Data-driven insights|30+ years of accelerated approval: trends, timelines, and impact. Available from: https://friendsofcancerresearch.org/blog/30-years-of-accelerated-approval-trends-timelines-and-impact/ [Last accessed on 18 Aug 2026].

411. Domike R, Raju GK, Sullivan J, Kennedy A. Expediting treatments in the 21st century: orphan drugs and accelerated approvals. Orphanet J Rare Dis. 2024;19:418.

412. Seoane-Vazquez E, Rodriguez-Monguio R, Powers JH 3rd. Analysis of US food and drug administration new drug and biologic approvals, regulatory pathways, and review times, 1980-2022. Sci Rep. 2024;14:3325.

413. Monge AN, Sigelman DW, Temple RJ, Chahal HS. Use of US food and drug administration expedited drug development and review programs by orphan and nonorphan novel drugs approved from 2008 to 2021. JAMA Netw Open. 2022;5:e2239336.

414. Confirmatory trials: timing is everything. Available from: https://premier-research.com/perspectives/accelerated-approval-and-confirmatory-trials-timing-is-everything/ [Last accessed on 18 Aug 2026].

415. Beakes-Read G, Neisser M, Frey P, Guarducci M. Analysis of FDA's accelerated approval program performance December 1992-December 2021. Ther Innov Regul Sci. 2022;56:698-703.

416. Omae K, Onishi A, Sahker E, Furukawa TA. US food and drug administration accelerated approval program for nononcology drug indications between 1992 and 2018. JAMA Netw Open. 2022;5:e2230973.

417. Beaver JA, Pazdur R. “Dangling” accelerated approvals in oncology. N Engl J Med. 2021;38:e684.

418. Naci H, Shahzad M, Murphy P, et al. Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration’s accelerated approval pathway: retrospective observational study and economic evaluation. BMJ Med. 2025;4:e001934.

419. Zhang AD, Puthumana J, Downing NS, Shah ND, Krumholz HM, Ross JS. Assessment of clinical trials supporting US food and drug administration approval of novel therapeutic agents, 1995-2017. JAMA Netw Open. 2020;3:e203284.

420. From an idea to the marketplace: the Journey of an animal drug through the approval process. Available from: https://www.fda.gov/animal-veterinary/animal-health-literacy/idea-marketplace-journey-animal-drug-through-approval-process#:~:text=CVM's%20approval%20of%20the%20NADA,impact%20on%20the%20environment;%20and [Last accessed on 18 Aug 2026].

421. FDA animal drug regulation: how it compares to human drugs. Available from: https://intuitionlabs.ai/articles/fda-animal-drug-regulation [Last accessed on 18 Aug 2026].

422. Understanding FDA pathways for animal drugs. Available from: https://www.avma.org/resources-tools/animal-health-and-welfare/animal-health/understanding-fda-pathways-animal-drugs#:~:text=Understanding%20the%20various%20pathways%20by,rare%20circumstances%E2%80%94emergency%20use%20authorization [Last accessed on 18 Aug 2026].

423. Minor Use/Minor Species. Available from: https://www.fda.gov/animal-veterinary/development-approval-process/minor-useminor-species [Last accessed on 18 Aug 2026].

424. Lau E. Tending to animals on 'the whole ark'. VIN News. 2022. Available from: https://news.vin.com/default.aspx?pid=210&catId=620&Id=11289647#:~:text=*%20The%20nearly%2020%2Dyear%2D,%2C%20honeybees%2C%20ferrets%20and%20cattle [Last accessed on 18 Aug 2026].

425. Approved Animal Drug Products (Green Book). Available from: https://www.fda.gov/animal-veterinary/products/approved-animal-drug-products-green-book [Last accessed on 18 Aug 2026].

426. Innovation in Animal Drug Development. Available from: https://www.fda.gov/animal-veterinary/animal-health-literacy/innovation-animal-drug-development#:~:text=In%20December%202021%2C%20FDA%20conditionally,associated%20with%20chronic%20kidney%20disease [Last accessed on 18 Aug 2026].

427. Vollert J, Schenker E, Macleod M, et al. Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals. BMJ Open Sci. 2020;4:e100046.

428. ARRIVE Guidelines. Available from: https://arriveguidelines.org/ [Last accessed on 18 Aug 2026].

429. Percie Du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal researchThe ARRIVE guidelines 2.0: updated guidelines for reporting animalresearch. BMJ Open Sci. 2020;4:e100115.

430. Pound P, Ritskes-Hoitinga M. Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. J Transl Med. 2018;16:304.

431. Gopinath C, Nathar T, Ghosh A, Hickstein D, Remington Nelson E. Contemporary animal models for human gene therapy applications. Curr Gene Ther. 2015;15:531-40.

432. Bailey AM, Mendicino M, Au P. An FDA perspective on preclinical development of cell-based regenerative medicine products. Nat Biotechnol. 2014;32:721-3.

433. Bailey AM, Arcidiacono J, Benton KA, Taraporewala Z, Winitsky S. United States food and drug administration regulation of gene and cell therapies. In: Galli MC, Serabian M, editors. Regulatory aspects of gene therapy and cell therapy products. Cham: Springer International Publishing; 2015. pp. 1-29.

434. Meer PJ, Graham ML, Schuurman H. The safety, efficacy and regulatory triangle in drug development: Impact for animal models and the use of animals. Eur J Pharmacol. 2015;759:3-13.

435. Phares SE, Young CM, Phillip KI, Trusheim MR. The next decade in cell and gene therapy. Drug Discov Today. 2026;31:104551.

436. Johnson RA, Rid A, Emanuel E, Wendler D. Risks of phase I research with healthy participants: a systematic review. Clin Trials. 2015;13:149-60.

437. Askitopoulou H. The Hippocratic principle “to help or at least to do no harm”. Transfus Clin Biol. 2024;31:174-80.

438. Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res. 2011;28:2379-85.

439. Enriquez J, Mims BMD, Trasti S, Furr KL, Grisham MB. Genomic, microbial and environmental standardization in animal experimentation limiting immunological discovery. BMC Immunol. 2020;21:50.

440. Lehr EJ, Rayat GR, Desai LS, Coe JY, Korbutt GS, Ross DB. Inbred or outbred? An evaluation of the functional allogenicity of farm sheep used in cardiac valve studies. J Thorac Cardiovasc Surg. 2006;132:1156-61.

441. Martino AT, Markusic DM. Immune response mechanisms against AAV vectors in animal models. Mol Ther Methods Clin Dev. 2020;17:198-208.

442. Shirley JL, De Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther. 2020;28:709-22.

443. Shieh PB, Kuntz NL, Dowling JJ, et al. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial. Lancet Neurol. 2023;22:1125-39.

444. Kornegay JN, Stedman HH, Lawlor MW, Byrne BJ, Childers MKC. First, do no harm: the role of preclinical animal models in predicting adverse events in gene therapy clinical trials for Duchenne muscular dystrophy and X-Linked myotubular myopathy. Rare Dis Orphan Drugs J. 2024;3:31.

445. Depla JA, Sogorb-Gonzalez M, Mulder LA, et al. Cerebral organoids: a human model for AAV capsid selection and therapeutic transgene efficacy in the brain. Mol Ther Methods Clin Dev. 2020;18:167-75.

446. Ramamurthy RM, Atala A, Porada CD, Almeida-Porada G. Organoids and microphysiological systems: promising models for accelerating AAV gene therapy studies. Front Immunol. 2022;13:1011143.

447. Harding J, Roberts RM, Mirochnitchenko O. Large animal models for stem cell therapy. Stem Cell Res Ther. 2013;4:23.

448. Rogers CS. Engineering large animal species to model human diseases. Curr Protoc Hum Genet. 2016;90:15.9.1-14.

449. Mullard A. Parsing clinical success rates. Nat Rev Drug Discov. 2016;15:447-447.

450. Data Safety and Monitoring Board. Available from: https://toolkit.ncats.nih.gov/module/clinical-trials-and-fda-review/serving-on-boards-to-review-and-monitor-clinical-trials/data-safety-and-monitoring-board/ [Last accessed on 19 Aug 2026].

451. Largent EA, Walter S, Childs N, et al. Putting participants and study partners FIRST when clinical trials end early. Alzheimers Dement. 2022;18:2736-46.

452. Ferrill MJ, Fakhriravari A, Hong L, Wedret JJ. A focus on evaluating major study limitations in order to apply clinical trials to patient care: implications for the healthcare team. Hosp Pharm. 2020;56:597-603.

453. Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156-64.

454. Byrne EM, Pascoe M, Cooper D, Armstrong TS, Gilbert MR. Challenges and limitations of clinical trials in the adolescent and young adult CNS cancer population: a systematic review. Neurooncol Adv. 2024;6:vdad159.

455. Marder SR, Laughren T, Romano SJ. Why are innovative drugs failing in phase III? Am J Psychiatry. 2017;174:829-31.

456. Van Norman GA. Phase II trials in drug development and adaptive trial design. JACC Basic Transl Sci. 2019;4:428-37.

457. Khan A, Fahl Mar K, Brown WA. The impact of underpowered studies on clinical trial results. Am J Psychiatry. 2018;175:188.

458. LinkedIn.com discussion. Peter Janiszewski, Ph.D. Available from: https://www.linkedin.com/posts/peterjaniszewski_analysis-of-phase-ii-and-phase-iii-clinical-activity-7418973763951554560-TD5f/ [Last accessed on 21 Aug 2026].

459. Feijoo F, Palopoli M, Bernstein J, Siddiqui S, Albright TE. Key indicators of phase transition for clinical trials through machine learning. Drug Discov Today. 2020;25:414-21.

460. Markey N, Howitt B, El-Mansouri I, Schwartzenberg C, Kotova O, Meier C. Clinical trials are becoming more complex: a machine learning analysis of data from over 16,000 trials. Sci Rep. 2024;14:3514.

461. Carlisle B, Kimmelman J, Ramsay T, Mackinnon N. Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials. Clin Trials. 2014;12:77-83.

462. Fernandez-Moure JS. Lost in translation: the gap in scientific advancements and clinical application. Front Bioeng Biotechnol. 2016;4:43.

463. Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022;12:3049-62.

464. Why do drugs fail. Available from: https://www.weatherden.com/why-do-drugs-fail-in-clinical-trials [Last accessed on 19 Aug 2026].

465. Cruelty to Animals. Available from: https://www.legislation.gov.uk/ukpga/1876/77/pdfs/ukpga_18760077_en.pdf [Last accessed on 19 Aug 2026].

466. Clutton RE. An anglocentric history of anaesthetics and analgesics in the refinement of animal experiments. Animals. 2020;10:1933.

467. Animal Welfare Act. Available from: https://www.nal.usda.gov/animal-health-and-welfare/animal-welfare-act [Last accessed on 21 Aug 2026].

468. Kirk RGW, Ramsden E. “Havens of mercy”: health, medical research, and the governance of the movement of dogs in twentieth-century America. Hist Philos Life Sci. 2021;43:126.

469. Russell WMS, Burch RL. The principles of humane experimental technique. London: Methuen, 1959. Available from: https://norecopa.no/textbase/the-principles-of-humane-experimental-technique [Last accessed on 21 Aug 2026].

470. Balls M. Replacement of animal procedures: alternatives in research, education and testing. Lab Anim. 1994;28:193-211.

471. Metzger MM. Knowledge of the animal welfare act and animal welfare regulations influences attitudes toward animal research. J Am Assoc Lab Anim Sci. 2015;54:70-5.

472. Kaplan BL, Hoberman AM, Slikker W, et al. Protecting human and animal health: the road from animal models to new approach methods. Pharmacol Rev. 2024;76:251-66.

473. Sewell F, Alexander-White C, Brescia S, et al. New approach methodologies (NAMs): identifying and overcoming hurdles to accelerated adoption. Toxicol Res. 2024;13:tfae044.

474. Marin Biologic Laboratories. Transforming preclinical safety testing: The FDA’s roadmap to replacing animal studies with new approach methodologies (NAMs). MAvailable from: https://www.marinbio.com/transforming-preclinical-safety-testing-the-fdas-roadmap-to-replacing-animal-studies-with-human-relevant-models-and-technologies/ [Last accessed on 28 Sep 2026].

475. FDA announces plan to phase out animal testing requirement for monoclonal antibodies and other drugs. Available from: https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs [Last accessed on 19 Aug 2026].

476. EPA new approach methods work plan: reducing use of vertebrate animals in chemical testing. Available from: https://www.epa.gov/chemical-research/epa-new-approach-methods-work-plan-reducing-use-vertebrate-animals-chemical [Last accessed on 19 Aug 2026].

477. Regulatory acceptance of new approach methodologies (NAMs) to reduce animal testing. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/research-development/ethical-use-animals-medicine-testing/regulatory-acceptance-new-approach-methodologies-nams-reduce-animal-use-testing#:~:text=New%20approach%20methodologies%20(NAMs)%20refer,used%20in%20regulatory%20decision%2Dmaking [Last accessed on 19 Aug 2026].

478. PMDA’s Initiatives. Available from: https://www.pmda.go.jp/english/review-services/0022.html#:~:text=PMDA's%20Initiatives,international%20stakeholders%20including%20regulatory%20authorities [Last accessed on 19 Aug 2026].

479. Roadmap to Reducing Animal Testing in Preclinical Safety Studies. Available from: https://www.fda.gov/files/newsroom/published/roadmap_to_reducing_animal_testing_in_preclinical_safety_studies.pdf#:~:text=1%20Over%2090%25%20of%20drugs%20that%20appear,due%20to%20safety%20and/or%20efficacy%20issues%20(1) [Last accessed on 19 Aug 2026].

480. Rider C. SOT statement on the use of animals in research and new approach methodologies, 2025. Available from: https://toxchange.toxicology.org/blogs/cynthia-rider1/2025/05/01/sot-statement-on-the-use-of-animals-in-research-an [Last accessed on 19 Aug 2026].

481. Stein M, Elefteriou F, Busse B, et al. Why animal experiments are still indispensable in bone research: a statement by the european calcified tissue society. J Bone Miner Res. 2023;38:1045-61.

482. Laman JD, Kooistra SM, Clausen BE. Reproducibility issues: avoiding pitfalls in animal inflammation models. In: Clausen BE, Laman JD, editors. Inflammation. New York, NY: Springer; 2017. pp. 1-17.

483. The age of animal experiments may be waning. Available from: https://www.scientificamerican.com/article/the-age-of-animal-experiments-may-be-waning/ [Last accessed on 19 Aug 2026].

484. Hopster J. The speciesism debate: intuition, method, and empirical advances. Animals. 2019;9:1054.

485. Singer P. All animals are equal. In: Regan T, Singer P, editors. Animal rights and human obligations. New Jersey: Prentice-Hall, 1989, pp. 148-62. Available from: https://spot.colorado.edu/~heathwoo/phil1200,Spr07/singer.pdf [Last accessed on 19 Aug 2026].

486. Browning H, Veit W. The sentience shift in animal research. New Bioethics. 2022;28:299-314.

487. Brønstad A, Newcomer CE, Decelle T, Everitt JI, Guillen J, Laber K. Current concepts of harm-benefit analysis of animal experiments - report from the AALAS-FELASA working group on harm-benefit analysis - part 1. Lab Anim. 2016;50:1-20.

488. Landi M, Everitt J, Berridge B. Bioethical, reproducibility, and translational challenges of animal models. ILAR J. 2022;62:60-5.

489. Grimm H, Dusseldorp M. The (re)turn of the 3Rs: an inquiry into the normative nature of Russell and Burch’s principles of humane experimental technique - their misunderstanding, reform and implementation through an ethics tool. Lab Anim. 2025;59:556-69.

490. Silk SB, Hampton LL, Brown PA. What investigators need to know about the use of animals. ILAR J. 2014;54:324-8.

491. Animal and Plant Health Inspection Service. Available from: https://www.aphis.usda.gov/ [Last accessed on 19 Aug 2026].

492. Animal Welfare (OLAW). Available from: https://grants.nih.gov/policy-and-compliance/policy-topics/animal-welfare [Last accessed on 19 Aug 2026].

493. Directives. Available from: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:en:PDF [Last accessed on 19 Aug 2026].

494. Petetta F, Ciccocioppo R. Public perception of laboratory animal testing: historical, philosophical, and ethical view. Addict Biol. 2020;26:e12991.

495. Matrana MR, Campbell B. Precision medicine and the institutional review board: ethics and the genome. Ochsner J. 2020;20:98-103.

496. The ethics of rare disease clinical trials: balancing innovation, urgency, and responsibility. Available from: https://uncommoncures.com/the-ethics-of-rare-disease-clinical-trials-balancing-innovation-urgency-and-responsibility/ [Last accessed on 19 Aug 2026].

497. Coors M, Bauer L, Edwards K, et al. Ethical issues related to clinical research and rare diseases: 15th Gordon L. Snider critical issues workshop, April 1, 2016, Bethesda, Maryland. Transl Sci Rare Dis. 2017;2:175-94.

498. Bertout JA, Baneux PJR, Robertson-Plouch CK. Recommendations for ethical review of veterinary clinical trials. Front Vet Sci. 2021;8:715926.

499. Baneux PJR, Bertout JA, Middleton JR, et al. Perspectives on implementing veterinary clinical studies committees. J Am Vet Med Assoc. 2023;261:1-6.

500. Quain A, Ward MP, Mullan S. Ethical challenges posed by advanced veterinary care in companion animal veterinary practice. Animals. 2021;11:3010.

501. Principles of veterinary medical ethics of the AVMA. Available from: https://www.avma.org/resources-tools/avma-policies/principles-veterinary-medical-ethics-avma [Last accessed on 19 Aug 2026].